Scientific article
Open access

Conjunctival melanoma targeted therapy: MAPK and PI3K/mTOR pathways inhibition

Published inInvestigative Ophthalmology & Visual Science, vol. 60, no. 7, p. 2764-2772
Publication date2019

To analyze the activity of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinases/mechanistic target of rapamycin (PI3K/mTOR) pathways in benign and malignant conjunctival melanocytic proliferations and explore whether specific inhibitors can suppress growth of conjunctival melanoma (CJM) cells.

  • Adult
  • Aged
  • 80 and over
  • Antineoplastic Agents/therapeutic use
  • Benzimidazoles/therapeutic use
  • Blotting
  • Western
  • Conjunctival Neoplasms/drug therapy/enzymology/pathology
  • Female
  • Fluorescent Antibody Technique
  • Indirect
  • Humans
  • Imidazoles/therapeutic use
  • Indazoles/therapeutic use
  • Male
  • Melanoma/drug therapy/enzymology/pathology
  • Middle Aged
  • Mitogen-Activated Protein Kinases/antagonists & inhibitors
  • Molecular Targeted Therapy
  • Phosphatidylinositol 3-Kinases/drug effects
  • Protein Kinase Inhibitors/therapeutic use
  • Proto-Oncogene Proteins B-raf/genetics
  • Pyridones/therapeutic use
  • Pyrimidinones/therapeutic use
  • Quinolines/therapeutic use
  • Sulfonamides/therapeutic use
  • TOR Serine-Threonine Kinases/antagonists & inhibitors
  • Tumor Cells
  • Cultured
Research group
Citation (ISO format)
EL ZAOUI, Ikram et al. Conjunctival melanoma targeted therapy: MAPK and PI3K/mTOR pathways inhibition. In: Investigative Ophthalmology & Visual Science, 2019, vol. 60, n° 7, p. 2764–2772. doi: 10.1167/iovs.18-26508
Main files (1)
Article (Published version)
ISSN of the journal0146-0404

Technical informations

Creation04/16/2020 12:36:00 PM
First validation04/16/2020 12:36:00 PM
Update time03/15/2023 9:32:03 PM
Status update03/15/2023 9:32:02 PM
Last indexation02/12/2024 1:11:48 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack